Andere Sprachen Sutro Biopharma, Inc.

Aktien

A2N6SG

US8693671021

STRO

Realtime-Estimate Cboe BZX Andere Börsenplätze 19:47:59 01.05.2024			% 5 Tage	% 1. Jan.
3,555 ^USD	+4,71 %		+1,87 %	-17,60 %

03.04.	SUTRO BIOPHARMA, INC. : Piper Sandler bekräftigt seine Kaufempfehlung	ZM
03.04.	SUTRO BIOPHARMA, INC. : Truist Securities behält die Bewertung Kaufen bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial	30.04.
Sutro Biopharma : Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”	04.04.
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering	02.04.
Ipsen and Sutro Biopharma Announce Exclusive Global Licensing Agreement for an ADC Targeting Solid Tumors	02.04.
Winfarm : Atos, Ipsen, Voltalia...les valeurs à suivre aujourd'hui à Paris -	02.04.
Ipsen : signature d'un accord exclusif avec Sutro Biopharma	02.04.
Ipsen : accord de licence mondiale avec Sutro Biopharma	02.04.
Ipsen Signs Licensing Deal for Cancer-targeting Antibody Conjugate with Sutro Biopharma	02.04.
Ipsen rachète les droits mondiaux de l'anticancéreux STRO-003 à Sutro Biopharma	02.04.
Health Care Climbs on Weight-Loss Drug Excitement -- Health Care Roundup	26.03.
Sutro Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	25.03.
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones	25.03.
Sutro Biopharma to Participate in Upcoming Investor Conferences	06.02.
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC	04.01.
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRa-Targeting ADC	04.01.
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR-targeted ADC, on January 4, 2024	15.12.
Sutro Biopharma, Inc.(NasdaqGM:STRO) dropped from NASDAQ Biotechnology Index	15.12.
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024	14.12.
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed, Refractory CBF/GLIS Presented at ASH 2023	12.12.
Sutro Biopharma, Inc. Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023	11.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Sutro Biopharma, Inc.

Aktien

A2N6SG

US8693671021

STRO

Andere Sprachen

Filter